Zhang Yan, Liao Qin-ping, Yu Li, Zhao Jian, Chen Chun-ling
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Fu Chan Ke Za Zhi. 2005 Aug;40(8):558-61.
To explore an efficient way to modulate the expression of estrogen receptor (ER) alpha and beta, and to build up a model of endometrial cancer cell expressing predominantly one isoform of ER and to verify the roles of ER alpha and beta in the tumorigenesis of endometrial cancer associated with estrogen and tamoxifen (TAM).
A series of oligodeoxyribonucleotides (ODN) against alpha or beta regions of ER alpha or beta were synthesized and tested in human endometrial cancer cell lines (Ishikawa) that express functional ER alpha and beta. The expressions of two ER isoforms were detected by western blot using specific antibodies. Then we studied the change of Ishikawa proliferation in response to 17beta-estradiol and TAM under the influence of antisense ODN.
(1) Transfection with antisense ODN directed against the ERalpha and ERbeta could significantly inhibit target protein production. (2) 17beta-estradiol could increase the proliferation of Ishikawa cells, but they lost the ability to proliferate in response to 17beta-estradiol after transfected with ERalpha antisense ODN especially at hours 24, 48 and 72 (P < 0.05). There was no obvious change in cell numbers of Ishikawa in response to 17beta-estradiol which were transfected with ERbeta antisense ODN. (3) TAM could also increase the growth of Ishikawa cells. After transfected with ERalpha antisense ODN, the cells lost the ability to proliferate in response to TAM at hours 24, 48 and 72 (P < 0.05). The inhibition was also seen in Ishikawa cells transfected with ERbeta antisense ODN at hour 72.
(1) Antisense ODN directed against the ERalpha or ERbeta can inhibit the expression of ERalpha or ERbeta effectively. (2) ERalpha may be the primary receptor in the proliferation of Ishikawa cells in response to 17beta-estradiol. Both ERalpha and ERbeta are involved in agonist impact of TAM on endometrial cancer cells.
探索一种有效调节雌激素受体(ER)α和β表达的方法,建立主要表达一种ER亚型的子宫内膜癌细胞模型,并验证ERα和β在雌激素及他莫昔芬(TAM)相关子宫内膜癌发生中的作用。
合成一系列针对ERα或β的α或β区域的寡脱氧核糖核苷酸(ODN),并在表达功能性ERα和β的人子宫内膜癌细胞系(Ishikawa)中进行检测。使用特异性抗体通过蛋白质免疫印迹法检测两种ER亚型的表达。然后我们研究了在反义ODN影响下,Ishikawa细胞对17β-雌二醇和TAM反应时增殖的变化。
(1)用针对ERα和ERβ的反义ODN转染可显著抑制靶蛋白的产生。(2)17β-雌二醇可增加Ishikawa细胞的增殖,但在用ERα反义ODN转染后,尤其是在24、48和72小时,它们失去了对17β-雌二醇反应而增殖的能力(P<0.05)。用ERβ反义ODN转染的Ishikawa细胞对17β-雌二醇反应时细胞数量无明显变化。(3)TAM也可增加Ishikawa细胞生长。在用ERα反义ODN转染后,细胞在24、48和72小时失去了对TAM反应而增殖的能力(P<0.05)。在72小时时,用ERβ反义ODN转染的Ishikawa细胞也出现了抑制作用。
(1)针对ERα或ERβ的反义ODN可有效抑制ERα或ERβ的表达。(2)ERα可能是Ishikawa细胞对17β-雌二醇反应增殖中的主要受体。ERα和ERβ均参与TAM对子宫内膜癌细胞的激动剂作用。